Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SYBX 
Synlogic Inc (SYBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SYBX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.48% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.60M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 0.54 | 52 Weeks Range 0.90 - 1.96 | Updated Date 09/13/2025 |
52 Weeks Range 0.90 - 1.96 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.18% | Return on Equity (TTM) -7.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -258719 | Price to Sales(TTM) 1652.07 |
Enterprise Value -258719 | Price to Sales(TTM) 1652.07 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 0.18 | Shares Outstanding 11698900 | Shares Floating 3605607 |
Shares Outstanding 11698900 | Shares Floating 3605607 | ||
Percent Insiders 11.25 | Percent Institutions 64.65 |
Upturn AI SWOT
Synlogic Inc
Company Overview
History and Background
Synlogic Inc. was founded in 2014, pioneering the field of synthetic biology to develop novel living medicines. It has focused on engineering microbial therapies to treat various metabolic and immunological diseases. They went public in 2017.
Core Business Areas
- Synthetic Biologic Medicines: Synlogic focuses on creating Synthetic Biologic Medicines (SBMs), which are engineered microbial strains designed to perform specific therapeutic functions within the body.
Leadership and Structure
The leadership team consists of Aoife Brennan, Ph.D., President and CEO. The organizational structure is typical of a biotechnology company, with research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- SYNB1934: SYNB1934 is Synlogic's lead investigational drug candidate, designed to treat phenylketonuria (PKU). It is an engineered strain of E. coli that consumes phenylalanine. There is no current market share for this product as it is still under clinical development. Competitors in PKU treatment include BioMarin Pharmaceutical Inc. (KUVAN and PALYNZIQ) and Dimension Therapeutics (gene therapy approach).
- SYNB8802: SYNB8802 is designed to treat Homocystinuria (HCU). It is an engineered strain of E. coli that consumes homocysteine. There is no current market share for this product as it is still under clinical development. Few competitors currently exist focusing on symptomatic management with diet and betaine anhydrous.
Market Dynamics
Industry Overview
The industry is the rapidly growing field of synthetic biology and engineered therapeutics, which is highly competitive and innovative. It involves companies developing novel biological solutions for various diseases.
Positioning
Synlogic is positioned as a pioneer in the Synthetic Biologic Medicines field. Its competitive advantage lies in its proprietary technology platform for engineering microbial therapeutics.
Total Addressable Market (TAM)
The TAM for metabolic and immunological diseases is substantial, estimated to be in the billions of dollars annually. Synlogic is targeting specific niche areas with high unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary synthetic biology platform
- Novel approach to treating metabolic disorders
- Strong intellectual property portfolio
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other disease areas
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biotechnology companies
Competitors and Market Share
Key Competitors
- BMY
- MRK
- LLY
Competitive Landscape
Synlogic faces competition from established pharmaceutical companies and other biotechnology companies developing therapies for similar indications. Its competitive advantage lies in its unique Synthetic Biologic Medicines platform. Market share numbers above are estimates of the total PKU & HCU market with competitors such as BMY and MRK involved through traditional pharmaceutical means.
Growth Trajectory and Initiatives
Historical Growth: Synlogic's growth has been driven by advancements in its technology platform and progress in clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of its Synthetic Biologic Medicines. Analyst estimates vary widely based on the perceived probability of clinical success.
Recent Initiatives: Recent initiatives include focusing on core clinical programs, optimizing manufacturing processes, and pursuing strategic partnerships.
Summary
Synlogic is a clinical-stage biotechnology company pioneering Synthetic Biologic Medicines for metabolic and immunological diseases. It has a promising technology platform and a novel approach to addressing unmet medical needs. However, it faces the inherent risks of clinical development, requiring positive trial results and successful regulatory approval. Success will depend on partnerships and managing cash burn effectively to reach pivotal milestones. Synlogic is currently trading near its cash value and a clinical success will substantially improve its value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Synlogic Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synlogic Inc
Exchange NASDAQ | Headquaters Winchester, MA, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.synlogictx.com |
Full time employees 1 | Website https://www.synlogictx.com | ||
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.